Vimta Labs (BOM:524394) Peter Lynch Fair Value: ₹294.98 (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524394 Vimta Labs Ltd BOM:524394
87 GF Score
Price ₹635.40
GF Value ₹513.74
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Vimta Labs Peter Lynch Fair Value?

Vimta Labs BOM:524394 +1.03% 87 Peter Lynch Fair Value is ₹294.98 as of Sep. 10, 2026. GuruFocus rates BOM:524394 with a GF Score™ of 87/100 and a GF Value™ of ₹513.74 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 26 Medical Diagnostics & Research companies, Vimta Labs ranks better than 53.85% on this metric.

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Vimta Labs's PEG is 1. Vimta Labs's 5-Year TTM EBITDA Growth Rate is 16.45. Vimta Labs's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₹17.93. Therefore, the Peter Lynch Fair Value for today is ₹294.98.

As of today (2026-09-10), Vimta Labs's share price is ₹635.40. Vimta Labs's Peter Lynch fair value is ₹294.98. Therefore, Vimta Labs's Price to Peter Lynch Fair Value Ratio for today is 2.15.


The historical rank and industry rank for Vimta Labs's Peter Lynch Fair Value or its related term are showing as below:

BOM:524394' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.42   Med: 1.35   Max: 3.58
Current: 2.15


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Vimta Labs was 3.58. The lowest was 0.42. And the median was 1.35.


BOM:524394's Price-to-Peter-Lynch-Fair-Value is ranked better than
53.85% of 26 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.205 vs BOM:524394: 2.15

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Vimta Labs  (BOM:524394) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 16.45 instead of 15 in this case.

Vimta Labs's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=635.40/294.98
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vimta Labs Peter Lynch Fair Value Related Terms


Vimta Labs Peter Lynch Fair Value Historical Data

* Premium members only.

The historical data trend for Vimta Labs's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vimta Labs Peter Lynch Fair Value Chart

Vimta Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.56 174.18 247.90 370.00 305.41

Vimta Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 398.00 364.48 330.60 305.41 294.98

BOM:524394 vs TMO, DHR, NTRA: Peter Lynch Fair Value Comparison

For the Diagnostics & Research subindustry, Vimta Labs's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vimta Labs Price-to-Peter-Lynch-Fair-Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Vimta Labs's Price-to-Peter-Lynch-Fair-Value falls into.


BOM:524394
87GF Score
Vimta Labs Ltd BOM:524394
Peter Lynch Fair Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vimta Labs Peter Lynch Fair Value Calculation

Vimta Labs's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 16.45 *17.932
=294.98

Vimta Labs's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹17.93.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.

Frequently Asked Questions Learn more about Peter Lynch Fair Value →
What does a Peter Lynch Fair Value of ₹294.98 mean?
Vimta Labs (BOM:524394) has a Peter Lynch Fair Value of ₹294.98 as of Sep. 10, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Vimta Labs and its competitors. According to the industry distribution chart, Vimta Labs ranks #12 out of 26 companies in the Medical Diagnostics & Research industry, placing it in the top 46.2%.
Is Vimta Labs' Peter Lynch Fair Value too high?
Vimta Labs' current Peter Lynch Fair Value is ₹294.98. Based on the distribution chart, Vimta Labs ranks #12 out of 26 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimta Labs has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Peter Lynch Fair Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #12 out of 26 companies for Peter Lynch Fair Value. This puts Vimta Labs in the upper half of its industry. The industry median Peter Lynch Fair Value is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Diagnostics & Research company?
The median Peter Lynch Fair Value among Medical Diagnostics & Research companies is 2.21, based on 26 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median Peter Lynch Fair Value is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Peter Lynch Fair Value is ₹294.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹513.74, compared to a current price of ₹635.40 — trading 23.7% above its estimated fair value. The current Peter Lynch Fair Value is ₹294.98. Vimta Labs' overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Peter Lynch Fair Value is ₹294.98 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vimta Labs (BOM:524394) Overvalued in 2026?

Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued. The current stock price of ₹635.40 is trading 23.7% above its estimated GF Value™ of ₹513.74. GuruFocus considers Vimta Labs to be Modestly Overvalued.

Key valuation signals for BOM:524394:

  • Peter Lynch Fair Value: ₹294.98
  • GF Value™: ₹513.74 vs. price of ₹635.40 (23.7% above fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vimta Labs Business Description

Other Exchanges VIMTALABS:India
Address Plot No.141/2 & 142, IDA, Phase-II, Cherlapally, R. R. District, Hyderabad, TG, IND, 500051
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
87GF Score

Get the complete analysis for BOM:524394

Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹635.40
Price
₹513.74
GF Value